Updates are available Correction dated 2021-05-19
Click to view Correction: https://doi.org/10.1007/s12282-021-01251-y
-
Authors
Uematsu, Takayoshi
Nakashima, Kazutaka
Kikuchi, Mari
Kubota, Kazunori
Suzuki, Akihiko
Nakano, Shogo
Hirokaga, Kouichi
Yamaguchi, Ken
Saji, Shigehira
Iwata, Hiroji
- License Information
-
More Information
Article History
Received: 20 August 2019
Accepted: 9 November 2019
First Online: 16 November 2019
Change Date: 19 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-021-01251-y
Compliance with ethical standards
:
: Dr. Uematsu has nothing to disclose. Dr. Nakashima has nothing to disclose. Dr. Kikuchi has nothing to disclose. Dr. Kubota has nothing to disclose. Dr. Suzuki has nothing to disclose. Dr. Nakano has nothing to disclose. Dr. Hirokaga has nothing to disclose. Dr. YAMAGUCHI has nothing to disclose. Dr. Saji reports grants and personal fees (honoraria for lectures) from Eisai, grants and personal fees from Chugai, grants and personal fees from Astra Zeneca, grants and personal fees from Takeda, grants and personal fees from Novartis, grants and personal fees from Taiho, personal fees from Kyowahakko Kirin, personal fees from Pfizer, personal fees from Daiichi Sankyo, grants and personal fees from Nihon Kayaku, grants from Ono. Dr. Iwata reports grants and personal fees from Chugai, personal fees from AstraZeneca, personal fees from Daiichi Sankyo, grants and personal fees from Novartis, grants from MSD, grants and personal fees from Lilly, personal fees from Kyowa Hakko Kirin, personal fees from Pfizer, during the conduct of the study. However, Dr. Iwata confirms that total fee from each company is not over the limited fee determined by JBCS.
